Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe : a Central European Cooperative Oncology Group analysis
Authors:Čufer, Tanja (Author)
Ciuleanu, Tudor (Author)
Berzinec, Peter (Author)
Galffy, Gabriela (Author)
Jakopović, Marko (Author)
Jassem, Jacek (Author)
Jovanovic, Dragana (Author)
MIhaylova, Zhasmina (Author)
Ostoros, Gyula (Author)
Thallinger, Christiane (Author)
Zemanova, Milada (Author)
Zielinski, Christoph (Author)
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.
Keywords:non-small cell lung cancer, treatment, novel drugs, Central Europe, Southeastern Europe
Year of publishing:2020
Publisher:Wiley Periodicals, Inc. on behalf of AlphaMed Press
COBISS_ID:2048592241 Link is opened in a new window
ISSN on article:1549-490X
OceCobissID:521539609 Link is opened in a new window
DOI:10.1634/theoncologist.2019-0523 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Opis vira z dne 6. 12. 2019;
Files:.pdf PDF - Presentation file, download (341,24 KB)
URL URL - Source URL, visit
AlphaMed Press
Rights:© 2019 The Authors
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY-NC-ND 4.0, Creative Commons Attribution Non-Commercial No Derivatives 4.0 International
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:24.07.2020